Effect of O-acetylation on the antigenicity and glycoconjugate immunogenicity of the Streptococcus pneumoniae serotype 7F capsular polysaccharide.

Streptococcus pneumoniae glycoconjugates pneumococcal conjugate vaccines polysaccharides vaccines

Journal

Chembiochem : a European journal of chemical biology
ISSN: 1439-7633
Titre abrégé: Chembiochem
Pays: Germany
ID NLM: 100937360

Informations de publication

Date de publication:
04 Oct 2024
Historique:
revised: 26 09 2024
received: 18 08 2024
accepted: 01 10 2024
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 4 10 2024
Statut: aheadofprint

Résumé

Streptococcus pneumoniae is a bacterial pathogen causing diseases as severe as pneumonia, sepsis and meningitis. Commercial pneumococcal conjugate vaccines contain the 7F serotype, which is epidemiologically relevant and highly invasive. This serotype contains an O-acetyl group at the internal L-rhamnose of its polysaccharide repeating unit. Herein we report on the role of the O-acetyl moiety of 7F polysaccharide in both antigen recognition and the induction of a protective antibody response against 7F. Fully and partially de-O-acetylated 7F polysaccharides were chemically prepared and compared with the O-acetylated counterpart in their antigenicity and immunogenicity of their tetanus toxoid glycoconjugates. These comparative studies showed a slight but consistent decrease in the antigenicity for the fully de-O-acetylated polysaccharide, but not for the partly de-O-acetylated variant. The glycoconjugates derived from the O-acetylated and the fully de-O-acetylated polysaccharides had similar sizes and polysaccharide-to-protein ratio, and all proved both to be immunogenic and induce opsonophagocytic responses in mice. Nevertheless, the immune response elicited by the O-acetylated glycoconjugate was better in both quantity and quality, proving that the O-acetyl group is not strictly necessary but also not irrelevant for the antigenicity and immunogenicity of the 7F serotype polysaccharide and its glycoconjugates.

Identifiants

pubmed: 39363669
doi: 10.1002/cbic.202400684
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202400684

Informations de copyright

© 2024 Wiley‐VCH GmbH.

Auteurs

Jean Pierre Soubal (JP)

Finlay Vaccine Institute, Glycoconjugation, CUBA.

Aloyma Lugo (A)

Finlay Vaccine Institute, Glycoconjugation, CUBA.

Darielys Santana-Mederos (D)

Finlay Vaccine Institute, Glycoconjugation, CUBA.

Raine Garrido (R)

Finlay Vaccine Institute, Analysis, CUBA.

Laura M Rodriguez-Noda (LM)

Finlay Vaccine Institute, Immunology, CUBA.

Rocmira Perez-Nicado (R)

Finlay Vaccine Institute, Immunology, CUBA.

Yamilka Soroa-Millan (Y)

Finlay Vaccine Institute, Immunology, CUBA.

Mildrey Fariñas (M)

Finlay Vaccine Institute, Immunology, CUBA.

Yury Valdés-Balbín (Y)

Finlay Vaccine Institute, Glycoconjugation, CUBA.

Dagmar García-Rivera (D)

Finlay Vaccine Institute, Direction, CUBA.

Daniel García Rivera (DG)

University of Havana, Laboratory of Synthetic and Biomolecular Chemistry, Zapata y G, 10400, La Habana, CUBA.

Vicente Vérez-Bencomo (V)

Finlay Vaccine Institute, Direction, CUBA.

Classifications MeSH